PubMed

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP.

Diabetes Care. 2004 Jan;27(1):41-6.PMID: 14693964 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

Diabetologia. 2005 Jun;48(6):1093-104. Epub 2005 May 12.PMID: 15889234 [PubMed - indexed for MEDLINE]Related articles

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.

Betteridge DJ, Vergès B.

Diabetologia. 2005 Dec;48(12):2477-81. Epub 2005 Nov 10.PMID: 16283239 [PubMed - indexed for MEDLINE]Related articles

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH; QUARTET Study Group.

Diabetes Care. 2004 Jan;27(1):141-7.PMID: 14693980 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.PMID: 16860259 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.

Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G.

Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):167-74.PMID: 15386821 [PubMed - indexed for MEDLINE]Related articles

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.

Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group.

J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76. Erratum in: J Clin Endocrinol Metab. 2005 Feb;90(2):746. PMID: 15579760 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

Chow CC, Tsang LW, Sorensen JP, Cockram CS.

Diabetes Care. 1995 Mar;18(3):307-14.PMID: 7555472 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, Baumstark MW, Krebs K, Wieland H, März W.

Diabetes Care. 2003 Sep;26(9):2588-94.PMID: 12941723 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.

Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators.

Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):373-9. Epub 2007 Oct 24.PMID: 17919894 [PubMed - indexed for MEDLINE]Related articles

Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.

Schöndorf T, Karagiannis E, Posseldt RE, Forst T, Pfützner A.

Diabetes Technol Ther. 2009 Jun;11(6):379-83.PMID: 19459767 [PubMed - indexed for MEDLINE]Related articles

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.

Dailey GE 3rd, Mohideen P, Fiedorek FT.

Clin Ther. 2002 Sep;24(9):1426-38.PMID: 12380634 [PubMed - indexed for MEDLINE]Related articles

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.

Tessier D, Maheux P, Khalil A, Fülöp T.

Metabolism. 1999 Jul;48(7):897-903.PMID: 10421233 [PubMed - indexed for MEDLINE]Related articles